As part of Medicare Part D changes resulting from provisions in the Inflation Reduction Act (IRA), AmeriHealth has identified the top five drugs (by volume) that are impacted by these changes. These five drugs are no longer covered, moving to Non-Formulary effective January 1, 2025.
Preferred alternatives are listed below. We recognize that drug selection and prescriptive authority rests with the licensed and treating health care provider.
cyclosporine ophthalmic emulsion 0.05 %
| Restasis® ophthalmic emulsion 0.05 % (brand)
|
Levemir®
| Lantus®, Basaglar®, Toujeo®
Levemir FlexPen and vial were discontinued by the manufacturer as of 12.31.24
|
moxifloxacin ophthalmic solution 0.5 %
| ciprofloxacin ophthalmic solution 0.3 %
ofloxacin ophthalmic solution 0.3 %
|
lansoprazole
| omeprazole
esomeprazole
pantoprazole
Omeprazole and esomeprazole are also available over the counter
|
diphenoxylate-atropine oral 2.5-0.025 mg
| loperamide oral capsule 2 mg
Also available over the counter
|
You can view the full AmeriHealth drug list.
For more information about the Inflation Reduction Act (IRA) and Medicare Part D changes, please visit the Pharmacy & IRA resource page.
23-0223